Cannabis and Hemp Industry Investment News
It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun The first trial is a ra...
Lexaria provided Amari with its DehydraTECH technology, which delivers CBD to the body more quickly and effectively than traditional formulations Hund...
The new study programs will target NSAIDs, nicotine replacement therapies, tetrahydrocannabinol (THC), and erectile dysfunction Each study will evalu...
Lexaria Bioscience (CSE: LXX- Nasdaq: LEXXW) CEO Chris Bunka joined Steve Darling from Proactive to share news the company has released positive resul...
The company reported that by using its DehydraTECH technology CBD beverages demonstrated 93.4% potency one year after production Lexaria's first paten...
Two of the four planned studies using DehydraTECH with antivirals are progressing -- comprised of a SARS-CoV-2 infected human cell culture study (VIRA...
Lexaria Bioscience (CSE: LXX-NASDAQ: LEXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive to share details about the company’s three h...
In human study HYPER-H21-1, the recruiting of 24 volunteers with otherwise untreated pre- or mild-hypertension has begun, and dosing using a single 30...
Study design for HYPER-A21-1 and HYPER-A21-2, both animal studies, has been completed, and dosing is expected to begin in late February or early March...
Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 202...
The new programs come on the heels of a recently-closed oversubscribed financing worth US$11 million Lexaria’s prospective business partners expect ev...
Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredients Cannabis is the ...
Reese has over 40 years' experience in public and private businesses and was finance chief at a former Nasdaq-listed energy company "With the new capi...
Lexaria BioScience (NASDAQ: LEXX- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive to bring news the company is now trading on the Nasdaq...
It intends to use the net proceeds of the offering, which includes a $1.44 million up-size option, for R&D studies, patent and legal costs, and ge...
Lexaria has commissioned studies to evaluate DehydraTECH’s ability to enhance the delivery and efficacy of four additional antiviral drugs, including ...
The biotechnology company has agreed last month to sell the assets owned by its subsidiary Lexaria Canpharm for C$3.85 million to Hill Street, in whic...
Lexaria Bioscience (OTCQX:LXRP-CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company has announced that its DehydraTECH ...
The company's technology was found to "significantly" improve the delivery of two classes of antiviral drugs - a protease inhibitor and a reverse tran...
Lexaria Bioscience (CSE: LXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has agreed to sell certain non-core...
